Endobiliary radiofrequency ablation through an EUS-guided hepaticogastrostomy fistula for hilar malignant biliary stenosis

Endobiliary radiofrequency ablation (RFA) for malignant biliary strictures due to unresectable cholangiocarcinoma is reportedly expected to prolong the patency of self-expandable metallic stents (SEMS) [1–3]. Transpapillary endoscopic retrograde cholangiopancreatography (ERCP) has been reported for endobiliary RFA; however, a few reports discuss the approach from the fistula made during endoscopic ultrasound biliary drainage (EUS-BD)[4–5].

In a 75-year-old man with hilar cholangiocarcinoma (►Fig. 1), a plastic stent was deployed in the right hepatic duct. Left hepatic duct drainage using ERCP was difficult due to ductal stenosis. Thus, EUS-guided hepaticogastrostomy (EUS-HGS) was performed (►Fig. 2). Because the cholangitis relapsed 5 months after EUS-HGS, stent-in-stent (SIS) deployment of SEMS was considered. After SIS deployment of SEMS, endobiliary RFA was expected to be difficult. Therefore, endobiliary RFA was performed in anticipation of a longer patency period before SEMS deployment.

A guidewire was placed through the EUS-HGS fistula. An endobiliary RFA catheter (Habib EndoHPB Catheter, Boston Scientific Corporation, Marlborough, Massachusetts, United States) was guided to the stenosis site, which was ablated for 90 seconds through the EUS-HGS fistula (VIO 200D, Effect8, 7W, Erbe Elektromedizin GmbH, Tübingen, Germany) (►Fig. 3). An uncovered SEMS (HANAR-OSTENT uncover, M.I TECH, Gyeonggi, Korea) was deployed through the fistula. After that, a plastic stent (Thorough and Pass Type IT, GADELIUS MEDICAL, Tokyo, Japan) was inserted into the EUS-HGS fistula after SEMS deployment to maintain the EUS-HGS fistula. ERCP was then performed. A guidewire was inserted into the right hepatic duct and another uncovered SEMS (ZEOSTENT V, Zeon Medical Inc., Tokyo, Japan) was deployed therein (►Fig. 4, ►Video 1). There was

►Fig. 1 Contrast-enhanced computed tomography revealed a hilar cholangiocarcinoma.

►Fig. 2 A plastic stent was deployed in the right hepatic duct and drainage of the left hepatic duct was performed using endoscopic ultrasound-guided hepaticogastrostomy.

►Fig. 3 An endobiliary radiofrequency ablation catheter was guided to the stenosis site, which was ablated for 90 seconds.

►Fig. 4 Stent-in-stent deployment of self-expandable metallic stent was performed.

minor postprocedural liver damage due to mild cholangitis; however, no serious adverse events were observed.

Conclusions

Reintervention was possible through the EUS-BD fistula. Endobiliary RFA from the EUS-BD fistula is effective when the guidewire from the transpapillary approach cannot pass the biliary stricture.

VIDEO

► **Video 1** After cholangiography of the fistula site, the stenosis was ablated. An uncovered SEMS was deployed through the fistula. Then, another uncovered SEMS was deployed in the right hepatic duct with transpapillary ERCP.

References

- [1] Cho JH, Jeong S, Kim EJ et al. Long-term results of temperature-controlled endobiliary radiofrequency ablation in a normal swine model. *Gastrointest Endosc* 2018; 87: 1147–1150
- [2] Lee YN, Jeong S, Choi HJ et al. The safety of newly developed automatic temperature-controlled endobiliary radiofrequency ablation system for malignant biliary strictures: A prospective study. *J Gastroenterol Hepatol* 2019; 34: 1454–1459
- [3] Larghi A, Rimbasi M, Tringali A et al. Endoscopic radiofrequency biliary ablation treatment: A comprehensive review. *Dig Endosc* 2019; 31: 245–255
- [4] Inoue T, Ito K, Yoneda M. Antegrade radiofrequency ablation and stenting for biliary stricture thorough endoscopic ultrasound-guided hepaticogastrostomy. *Dig Endosc* 2018; 30: 793–794
- [5] Inoue T, Ibusuki M, Kitano R et al. Endoscopic ultrasound-guided antegrade radiofrequency ablation and metal stenting with hepaticogastrostomy for malignant biliary obstruction: a prospective preliminary study. *Clin Transl Gastroenterol* 2020; 11: e00250

Bibliography

Endosc Int Open 2021; 09: E699–E700

DOI 10.1055/a-1393-5497

ISSN 2364-3722

© 2021. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Competing interests

The authors declare that they have no conflict of interest.

The authors

Naosuke Kuraoka, Satoru Hashimoto, Shigeru Matsui

Department of Gastroenterology, Saiseikai Kawaguchi General Hospital

Corresponding author

Naosuke Kuraoka, MD, PhD

Department of Gastroenterology, Saiseikai Kawaguchi General Hospital, 5-11-5 Nishikawaguchi, Kawaguchi, Saitama, 332-8558, Japan
Fax: +81-48-256-5703
kuraoka0926@gmail.com